Copper (II)-chelating malonohydrazide derivative with in vitro and in vivo anticancer efficacy via reactive oxygen species (ROS) & apoptosis induction.
Elesclomol (STA-4783) is a copper (II)-chelating malonohydrazide derivative that exerts its in vitro and in vivo anticancer efficacy via reactive oxygen species (ROS)/oxidative stress & apoptosis induction in a Cu(II)-dependent manner (GI50 = 12 nM without vs. 129 nM with Cu2+ removal by TRIEN in K562 culture; typical conc. range 0.1-2 μM in cultures). Elesclomol chelates extracellular Cu(II) for mitochondria delivery, where upon Cu2+ reduction (to Cu+) & ROS generation, copper-free elesclomol then exits cells for continual Cu(II) shuttling and accumulation in mitochondria. In addition to Cu2+, elesclomol can also chelate Co2+ and Ni2+, but not Fe3+ or Zn2+.
Elesclomol is an investigational drug that exerts potent anticancer activity through the elevation of reactive oxygen species (ROS) levels and is currently under clinical evaluation as a novel anticancer therapeutic. Here we report the first description of selective mitochondrial ROS
MTH1 helps prevent misincorporation of ROS-damaged dNTPs into genomic DNA; however, there is little understanding of how MTH1 itself is regulated. Here, we report that MTH1 is regulated by polyubiquitination mediated by the E3 ligase Skp2. In melanoma cells, MTH1
Chemical communications (Cambridge, England), 54(31), 3835-3838 (2018-03-27)
A new fluorescence probe was developed for HClO detection under physiological conditions, which displayed fast response (t1/2 < 30 s) and large off-on fluorescence increase (>1000-fold) toward HClO with high sensitivity and selectivity. The probe was successfully applied for the
Frontiers in pharmacology, 8, 804-804 (2017-11-23)
In order to survive under conditions of low oxygen, cancer cells can undergo a metabolic switch to glycolysis and suppress mitochondrial respiration in order to reduce oxygen consumption and prevent excessive amounts of reactive oxygen species (ROS) production. Nucleus accumbens-1
Journal of inorganic biochemistry, 137, 22-30 (2014-05-07)
Elesclomol is an anticancer drug that is currently undergoing clinical trials. Elesclomol forms a strong 1:1 complex with Cu(II) and may exert its anticancer activity through the induction of oxidative stress and/or its ability to transport copper into the cell.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
